Laman UtamaARCT • NASDAQ
add
Arcturus Therapeutics Holdings Inc
$12.91
Selepas Waktu Dagangan:(0.00%)0.00
$12.91
Tutup: 25 Apr, 4:02:36 PTG GMT-4 · USD · NASDAQ · Penafian
Tutup sebelumnya
$12.89
Julat hari
$12.29 - $12.98
Julat tahun
$8.04 - $44.99
Permodalan pasaran
350.12J USD
Bilangan Purata
428.97K
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
NASDAQ
Berita pasaran
Invezz
1 hari lalu
Amaran risiko: ‘kemelesetan sederhana’ boleh menjejaskan tahap S&P 500 kepada 3,700
0.74%
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Hasil | 22.77J | -26.22% |
Perbelanjaan pengendalian | 12.38J | -1.02% |
Pendapatan bersih | -30.00J | -156.30% |
Margin untung bersih | -131.80 | -247.39% |
Pendapatan bagi setiap syer | -1.11 | -246.88% |
EBITDA | -32.58J | -86.60% |
Kadar cukai berkesan | 0.01% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 237.03J | -18.83% |
Jumlah aset | 344.07J | -19.87% |
Jumlah liabiliti | 103.09J | -31.68% |
Jumlah ekuiti | 240.98J | — |
Syer tertunggak | 27.12J | — |
Harga kepada buku | 1.45 | — |
Pulangan pada aset | -23.36% | — |
Pulangan pada modal | -29.77% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -30.00J | -156.30% |
Tunai daripada operasi | -284.00K | 54.85% |
Tunai daripada pelaburan | 0.00 | 100.00% |
Tunai daripada pembiayaan | 134.00K | 100.72% |
Perubahan bersih dalam tunai | -150.00K | 99.26% |
Aliran tunai bebas | 9.53J | 143.91% |
Perihal
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. As of 2021, vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. Wikipedia
Diasaskan
2013
Tapak web
Pekerja
175
